1. Home
  2. GBIO vs SCPH Comparison

GBIO vs SCPH Comparison

Compare GBIO & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • SCPH
  • Stock Information
  • Founded
  • GBIO 2016
  • SCPH 2013
  • Country
  • GBIO United States
  • SCPH United States
  • Employees
  • GBIO N/A
  • SCPH N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • SCPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • GBIO Health Care
  • SCPH Health Care
  • Exchange
  • GBIO Nasdaq
  • SCPH Nasdaq
  • Market Cap
  • GBIO 29.5M
  • SCPH 299.0M
  • IPO Year
  • GBIO 2020
  • SCPH 2017
  • Fundamental
  • Price
  • GBIO $5.77
  • SCPH $5.63
  • Analyst Decision
  • GBIO Buy
  • SCPH Buy
  • Analyst Count
  • GBIO 4
  • SCPH 3
  • Target Price
  • GBIO $10.67
  • SCPH $12.00
  • AVG Volume (30 Days)
  • GBIO 76.7K
  • SCPH 2.4M
  • Earning Date
  • GBIO 11-05-2025
  • SCPH 11-12-2025
  • Dividend Yield
  • GBIO N/A
  • SCPH N/A
  • EPS Growth
  • GBIO N/A
  • SCPH N/A
  • EPS
  • GBIO N/A
  • SCPH N/A
  • Revenue
  • GBIO $21,230,000.00
  • SCPH $49,969,000.00
  • Revenue This Year
  • GBIO N/A
  • SCPH $104.30
  • Revenue Next Year
  • GBIO N/A
  • SCPH $76.06
  • P/E Ratio
  • GBIO N/A
  • SCPH N/A
  • Revenue Growth
  • GBIO 61.15
  • SCPH 107.79
  • 52 Week Low
  • GBIO $3.00
  • SCPH $1.94
  • 52 Week High
  • GBIO $29.10
  • SCPH $6.28
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 50.66
  • SCPH 63.97
  • Support Level
  • GBIO $5.51
  • SCPH $4.33
  • Resistance Level
  • GBIO $6.04
  • SCPH $5.62
  • Average True Range (ATR)
  • GBIO 0.32
  • SCPH 0.04
  • MACD
  • GBIO -0.10
  • SCPH -0.01
  • Stochastic Oscillator
  • GBIO 26.80
  • SCPH 86.67

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About SCPH scPharmaceuticals Inc.

scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.

Share on Social Networks: